Upgrade your cell-free DNA experience
Know more. Learn how we have improved our Innatal® Prenatal Screen.
Progenity is dedicated to continuous product improvement. We have upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry.
In-depth verification and validation testing of the Innatal assay, using >1000 samples, was conducted as prescribed by multiple peer-reviewed guidelines.1,2,3
What did we find?
The Innatal Prenatal Screen is:
Precise – Agreement of >99% for repeatability and reproducibility4
Accurate – High concordance with known clinical outcomes4
Sensitive – Proven to identify affected fetuses with >99% sensitivity4
Specific – Proven to rule-out unaffected fetuses with >99% specificity4
Data Summary Sheet
A detailed summary of our verification and validation results.Download the data summary sheet >
Dive deeper on how this data uniquely impacts your practice by contacting us. We’ll give you direct access to our lab team.Email us >
- Jennings et al. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-55.
- Lacbawan et al. Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array. Arch Pathol Lab Med. 2012;136(1):14-9.
- Rehm et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-47.
- Progenity, Inc. Data on file.